Vaccinex, Inc. Announces Continuation of the SIGNAL Clinical Trial
September 09, 2016 09:45 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Sept. 09, 2016 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a clinical-stage biotechnology company engaged in the discovery and development of therapeutic monoclonal antibodies to treat...
Vaccinex, Inc. Receives Orphan Drug Designation from U.S. FDA for its Lead Antibody Product Candidate, VX15, as a Potential Treatment for Huntington’s Disease
August 23, 2016 10:15 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Aug. 23, 2016 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a clinical-stage biotechnology company engaged in the discovery and development of therapeutic monoclonal antibodies to treat...
Vaccinex Receives FDA Fast Track Designation for VX15 Antibody for the Treatment of Huntington’s Disease
August 01, 2016 10:05 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Vaccinex, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VX15 as a potential...
Vaccinex Announces Publication of Results From a Phase I Trial of Anti-Semaphorin 4D Antibody, VX15/2503, in Patients With Advanced Solid Tumors
October 20, 2015 13:17 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Oct. 20, 2015 (GLOBE NEWSWIRE) -- Vaccinex Inc., a clinical-stage biotechnology company engaged in the discovery and development of therapeutic monoclonal antibodies to treat cancer...
Vaccinex, Inc. Announces the Initiation of a Phase 2 Clinical Trial of Its Investigational VX15/2503 Antibody in Huntington's Disease (the SIGNAL Trial)
June 24, 2015 13:17 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., June 24, 2015 (GLOBE NEWSWIRE) -- Vaccinex, Inc. announced today that it has initiated a Phase 2 clinical trial to assess the safety, tolerability and efficacy of anti-semaphorin 4D...
Vaccinex Provides an Update on Its VX15/2503 Phase 1 Clinical Trial in Multiple Sclerosis Patients
March 31, 2015 13:17 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., March 31, 2015 (GLOBE NEWSWIRE) -- Vaccinex, Inc. today announced the successful completion of a multicenter phase 1, randomized, double-blind, placebo-controlled, single...
Vaccinex Signs Multi-Target Antibody Discovery Deal With Five Prime Therapeutics
March 19, 2015 13:30 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., March 19, 2015 (GLOBE NEWSWIRE) -- Vaccinex, Inc. announced today that the company has entered into a multi-target collaboration agreement with Five Prime Therapeutics, Inc. to...
Vaccinex Announces the Publication of Data Demonstrating Preclinical Efficacy in an Animal Model of Huntington Disease
February 17, 2015 11:05 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Feb. 17, 2015 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a clinical-stage immunotherapy company engaged in the discovery and development of therapeutic monoclonal antibodies, today announced...